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Background: Pregnancies complicated with pre-gestational diabetes mellitus are associated 
with an increased rate of adverse effects for both mother and fetus. Even though strict 
metabolic control of glucose & close monitoring and follow up by the tertiary unit reduces the 
risk of complications, pregnancy outcome is not as good as in healthy pregnancies. There are 
very few studies that have investigated the association of diet, metabolic control, and 
pregnancy outcome of pre-gestational diabetes mellitus pregnancies. 
Objectives: The study aims to determine the effects of diet during pregnancy in women with 
pre-gestational diabetes on pregnancy outcomes macrosomia and prematurity. 
Methods: A prospective longitudinal study of women with pre-gestational diabetes mellitus. 
This study is a part of a larger project (the DiaDoppler study) which was carried out by “the 
research group for pregnancy, fetal development, and birth” at Obstetrics and Gynecological 
Department of Haukeland University Hospital during the period 2013 – 2016. Women with 
pre-gestational diabetes in Hordaland county were referred to Haukeland University Hospital 
as soon as pregnancy was diagnosed. Finally, 49 women were included & followed 
longitudinally in the study. At the first prenatal visit, basic and health information was 
collected. Anthropometric measurements, blood samples & dietary data were collected three 
times during pregnancy such as around gestational weeks 9,24, and 36. Dietary intake was 
measured by 3-day dietary records in 26, 24, and 19 women, respectively. 
Results: Out of 49 deliveries 19 were macrosomia babies (39%). Gestational weight gain & 
Hb1Ac in 1st trimester were higher in women who had a macrosomia baby. No dietary factors 
were significantly different between women with macrosomia babies throughout pregnancy. 
Out of 49 deliveries, 15 babies (31%) were delivered preterm. Hb1Ac was higher in the 1st & 
2nd trimester of women with preterm delivery. Dietary factors associated with prematurity 
were dietary intake of fiber in 1st and 2nd trimester and lower intake of energy, fat, and protein 
in 2nd trimester. 
Conclusions: In this study, there are significant associations of metabolic control with birth 
outcomes, and low intake of energy, fat, protein in 2nd trimester in those women with preterm 
delivery. Higher Intake of dietary fiber particularly in 1st trimester was associated with 
increases in gestational age at birth. Macrosomia is associated with gestational weight gain & 
metabolic control, but not with dietary intake. More studies are needed to study the effect of 






Diabetes mellitus is an endocrine disorder of long-standing high blood glucose 
(hyperglycemia) due to relative or absolute insulin deficiency, insulin resistance, or both. 
Etiological risk factors are age, family history, physical activity, obesity, and dietary patterns. 
Diabetes mellitus in pregnancy is a major challenge for pregnancy outcomes and associated 
with increased risk of abortion, stillbirth, and malformation. Mothers with pre-gestational 
diabetes mellitus (PGDM) had a 2.6 % rate of stillbirth while this rate was 0.8 % in non-
diabetic mothers in 1998 in Norway (1). Appropriate nutrient intake plays a major role in the 
treatment of pregnant women with pre-gestational diabetes mellitus but has been surprisingly 
rarely investigated.  
1.2 Epidemiological perspective of Diabetes Mellitus 
The International Diabetes Federation (IDF) indicated that in 2013, 382 million people (8.3 % 
of the global population with equal rates in both women and men) had Diabetes mellitus 
(DM). 1.6 million people died due to DM worldwide in 2016, thus, it was the 7th leading 
cause of death globally. Global figures have risen until 2019 to approximately 482 million 
adults (20-79 years) who were living with DM while an increase to 700 million in 2045 is 
estimated. It is estimated that 10% of global health expenditure is spent on diabetes mellitus 
(2, 3.5). 
According to the Medical Birth Registry of Norway, 58 in 1000 pregnant woman had a 
diagnosis of diabetes mellitus in 2018, of these, the rates were as follows for the different 
types of DM  4.1/1000 type 1 DM, 1.9/1000 type 2 DM and 50/1000 Gestational Diabetes 
Mellitus (GDM) in Norway. In the county Hordaland figures were as follows 86.6/1000 
women had a diagnosis of DM in pregnancy in 2018:  5.5/1000 type 1 DM, 1.1/1000 type 2 
DM, and 75/1000 GDM (6). 
1.3 Types of Diabetes mellitus 
Diabetes mellitus can be classified into 1) Type1 Diabetes mellitus which has immune 
pathogenesis (mostly) and is characterized by severe insulin deficiency. 2) Type2 Diabetes 
mellitus, results from a combination of insulin resistance and less severe insulin deficiency. 3) 
Gestational diabetes mellitus, diabetes mellitus diagnosed during the period of pregnancy, 
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particularly in the 2nd or 3rd trimester of pregnancy, and 4) and other specific types of diabetes 
mellitus such as genetic defects of beta-cell function (MODY), diseases of the exocrine 
pancreas (cystic fibrosis, hemochromatosis), drug or chemical induced diabetes mellitus, 
infections (congenital rubella), etc. (7).   
Pre-gestational diabetes is defined as any type of diabetes diagnosed before pregnancy. 
Common heath consequences of Diabetes mellitus are risk of cardiovascular diseases, stroke, 
diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy. Diabetic retinopathy is 
one of the important causes of blindness and diabetic neuropathy of foot ulcers (8). Pre-
gestational diabetes mellitus is associated with worst pregnancy outcomes: increased rate of 
still birth, malformations, prematurity, and macrosomia. Since type 2 DM is usually occurring 
at later life stages, type 1 DM is most common in PGDM. 
1.3.1 Type1 Diabetes Mellitus (Type1DM)  
Type 1 Diabetes Mellitus, also called juvenile diabetes or insulin-dependent diabetes, appears 
during childhood or adolescence, but it can also develop in young adults. It is a chronic 
disease in which the pancreas (beta cells of islets of Langerhans) produces little or no insulin. 
Therefore, type 1 diabetes mellitus patients need replacement of the functions of β cells to 
achieve blood levels of glucose as close to the normal range as possible and to avoid 
complications from hyperglycemia. Insulin and Insulin analogues are used to solve the 
problem of patients with diabetes type1(9). 
Type1 Diabetic mellitus belongs to a family of human leucocyte antigen (HLA) associated 
immune-mediated organ-specific diseases. Genetic susceptibility is polygenic, with a 
contribution from the HLA region. Increased susceptibility to Type1 Diabetic Mellitus is 
inherited but the disease is not genetically predetermined (2). Type 1 Diabetic Mellitus is an 
autoimmune disorder; therefore, it can be associated with other specific autoimmune diseases 
such as autoimmune thyroid diseases, celiac diseases, Addison’s disease, and pernicious 
anemia (2). Type 1 diabetes has no cure and needs lifelong treatment. Treatment focuses on 
managing blood sugar levels with insulin, diet, physical activity, and lifestyle to prevent 
complications.  
More than 1.1 million children and adolescents below 20 years are living with Type 1 DM 
around the globe. Every year around 300 children get type1 diabetes mellitus in Norway (11). 
Approximately 28,000 type1 diabetic patients live in Norway in 2013 (0.6 percent of 
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population) (11,12). The number of pregnancies in women with pre-gestational diabetes in 
Norway is estimated to be 228 in 2018 according to the medical birth register. There are 
ethnic and racial disparities in women with pre-gestational diabetes (14).  
1.3.2 Type 2 Diabetes Mellitus (Type2DM) 
Type 2 Diabetes mellites is the most common type of Diabetes. Type2 DM is generally 
characterized by insulin resistance where insulin does not work properly. Type2 DM is 
common in older age, but its prevalence is increasing in younger ages due to a rising level of 
obesity, an unbalanced diet, and inadequate physical activity. There are several risk factors for 
Type2 DM such as a family history of Type2 DM, overweight or obesity, inadequate physical 
activity, ethnicity, history of gestational diabetes, increasing age, stress, and unhealthy diet. 
Physical activity, a healthy diet, avoid smoking, excessive intake of alcohol and added sugar, 
and maintain normal body weight are the key factors to prevent Type2 DM (15). In 
particularly the incidence of type 2 DM risk can be reduced by 20 - 30% when consuming 
high fiber in the diet (16). 
1.3.3 Maturity-onset Diabetes of the young (MODY) 
Maturity-onset diabetes of the young (MODY) is a genetically and clinically heterogeneous 
subtype of type 2 diabetes, comprises a heterogeneous group of monogenic disorders 
characterized by a primary defect in pancreatic β-cell function, early-onset, and autosomal 
dominant inheritance, expecting for about 1-5% of all diabetes diagnoses. Mutations in 14 
genes are responsible for most MODY cases described so far (17,18). 
1.3.4 Latent Autoimmune Disease in Adults (LADA) 
LADA is an autoimmune diabetes that is characterized by considerable degree of 
heterogeneity, it appears at any age. LADA is distinct from Type 1 DM due to its adult age of 
onset and slower progression towards insulin requirement. LADA may be a mix of type 1 and 
type 2 DM, anyway, patients with LADA present with clinical and biochemical features 
closer to Type 1 DM than Type 2 DM (19). 
1.3.5 Gestational Diabetes Mellitus (GDM) 
“Gestational diabetes mellitus (GDM) defined as any degree of glucose intolerance with an 
onset, or first recognition during pregnancy” (20). The Norwegian guidelines define 
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gestational diabetes as a fasting blood glucose level between 5.3 to 6.9 mmol/l and/or a two-
hour level of blood glucose between 9.0 and 11.0 mmol/l after oral glucose tolerance test (21). 
Gestational diabetes is the most common medical complication of pregnancy and associated 
with maternal and neonatal adverse outcomes. Pregnancy is associated with insulin resistance 
(IR) and hyperinsulinemia that may further develop into Gestational diabetes mellitus. During 
pregnancy, progressive insulin resistance starts around mid-pregnancy and progresses during 
the third trimester. While in early pregnancy, insulin secretion is not much changed. Insulin 
sensitivity starts to decline progressively, during the 2nd trimester of pregnancy and is further 
reduced during the rest of the pregnancy, being worst in the late third trimester. Insulin 
secretion increases gradually from 2nd trimester and peak in 3rd trimester. Insulin resistance 
usually disappears with the delivery and the disappearance of the placenta. Therefore, GDM 
usually develops in the late second trimester and disappears after delivery.  
GDM develops when a woman’s pancreas does not secrete enough insulin to keep up with the 
metabolic stress of insulin resistance (22). Also, increased maternal fat deposition, inadequate 
exercise, and increased calorie intake lead to this state of relative glucose intolerance. The 
decline of insulin sensitivity is mediated by increase level estrogen, human placental lactogen, 
progesterone and some other factors (22).  
The common risk factors for GDM are obesity, higher age, history of Gestational diabetes, 
family history of diabetes, and an ethnic group with high prevalence type2 diabetes (23). 
Women with GDM are at risk of developing type 2 diabetes in the future, Therefore, it is very 












1.4.1 Physiological Function of Insulin 
Figure 1. The production of insulin in the pancreas (24) 
As illustrated in figure 1, Pancreas contains exocrine ducts and endocrine islets of 
Langerhans. Islets of Langerhans are built up by 70-80% of beta cells, alfa, delta, and epsilon 
cells (24). 
Endocrine pancreas controls blood glucose in the human body by producing and releasing 
both insulin and glucagon to the blood. Insulin is coded for on chromosome 11 and 
synthesized in the beta cells of the pancreatic islets. Insulin is a peptide hormone and, consists 
of 51 amino acids. it is important for metabolism and utilization of energy from the ingested 
nutrients - especially glucose (25). Insulin is released upon when high glucose levels reach in 
blood. Insulin facilitates glucose entry into the muscle (glucose uptake) and other tissues via 
the GLU4 transporter, stimulates glucose into glycogen (storage) conversion in the liver 
(glycogenesis) and stimulate glycolysis (oxidation of glucose to pyruvate) in liver and 
muscles, promotes the synthesis of fatty acids in the liver (lipogenesis) and inhibits the 
breakdown of fat in adipose tissue, increases the uptake of amino acids in muscles and 
contributes in protein synthesis (26). After secretion, insulin enters the portal circulation and 
is carried to the liver. Around 50% of secreted insulin is extracted and degraded in the liver. 
The residue is broken down by the kidneys. The liver is the principal organ of glucose 
homeostasis (2). 
The brain is the major consumer of glucose and brain function depends on the continuous 
supply of glucose. Even though brain glucose uptake is obligatory, it is not dependent on 
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insulin. Insulin action in the fasting and postprandial states are different. In the fasting stage, 
its main action is to regulate glucose release by the liver but in the postprandial stage, it 
additionally promotes glucose uptake by fat and muscle (2).  
Cell membranes are not inherently permeable to glucose. So, glucose transport (GLUT) 
proteins carry glucose through the cell membranes. GLUT1, allow basal non-insulin 
stimulated glucose uptake into many cells. GLUT2 transports glucose into beta cells a 
prerequisite for glucose sensing. It is also present in the renal tubules and hepatocytes. 
GLUT3 enables noninsulin mediated glucose uptake into the brain neurons and placenta. 
GLUT4 facilitates much of the peripheral action of insulin. It is the channel for glucose 
uptake into muscle and adipose tissue following the stimulation of the insulin receptor. The 
insulin receptor is a glycoprotein, coded for on the short arm of chromosome 19, attached the 
membrane of many cells (2). 
1.4.2 Insulin therapy  
In the case of insulin-dependent diabetes, there are a variety of different insulin types being 
used to treat DM patients. Insulin types are classified according to their speed of onset, peak 
and duration of action into rapid-acting insulin, short-acting insulin, intermediate-acting 
insulin, and long-acting insulin.  
Rapid-acting insulin reaches a peak in action at approximately one hour but will last 2 to 4 
hours, while long-acting insulin releases slowly to reach the bloodstream and stabilizes a 
stable effect on blood glucose, and that remains constant for 24 hours. Long-acting insulin can 
be used in combination with rapid- or short-acting insulin.   
Insulin can be administered by a syringe, injection pen, or an insulin pump that delivers a 
continuous flow. It is administered through the subcutaneous, intramuscular, or intravenous 
route, or taken into the lungs by inhalation. Insulin dose can be adjusted for food intake, 
physical activity, and health-related problems (ex- vomiting). Self-monitoring of blood 
glucose will give guidance for insulin dosage adjustments. 
Insulin dose prior to diabetic pregnancy is determined by pre-pregnancy BMI, physical 
activity, and HbA1c levels. Mean weakly requirement of insulin dosage increase in 3 to 7 
weeks of diabetic pregnancy followed by a decline from week 7 to 15 weeks of pregnancy. 
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The weakly insulin dose gradually increases and reaches the maximum at 35 weeks of 
gestation and declined thereafter (27,28). 
Traditionally, patients with type1 DM have been thought to have lower BMI, however current 
trend indicates that the prevalence of overweight and obesity increases in type1 DM patients 
compared to the general population. Weight gain in type1 DM patients is related to clinical 
factors such as insulin therapy. Insulin is an anabolic hormone that inhibits protein catabolism 
and increases lipogenesis, resulting in fat accumulation. So, the intensity of insulin therapy 
influences weight gain. Despite the weight gain, insulin treatment reduces Hb1Ac and long-
term reduction of microvascular & macrovascular complications (29). Nowadays insulin 
therapies more closely mimic physiologic insulin secretion and do better glycemic control in 
diabetic patients (30). 
1.5 Diabetes and pregnancy 
1.5.1 Introduction in diabetic pregnancy 
Pre-existing diabetes in pregnancy is closely associated with increased risks both for the 
woman and the developing fetus. Miscarriage, pre-eclampsia, and preterm delivery are more 
common in women with pre-gestational diabetes (31). In addition, stillbirth, congenital 
malformations, macrosomia, birth injury, perinatal mortality, and postnatal hypoglycemia are 
common in babies born to women with diabetes (31). High blood glucose levels can harm the 
fetus, especially in the first 8 weeks of pregnancy (32). The risks of adverse outcomes are 
much lower with gestational diabetes than with pre-gestational diabetes (33). Recurrent 
hypoglycemia is more common in type 1 DM than type 2 DM (34). Adequate pre-
conceptional care, especially the level of glycemic control reduces the frequency of congenital 
malformations and improves the outcome of pregnancy (35). 
There are several challenges for maintaining normoglycemia in women with DM who become 
pregnant, including morning sickness, hormonal changes during pregnancy, and increasing 
adipose tissue deposits in pregnant women (32,36). 
Every pregnant woman is advised to follow some regulations to have a healthy baby, for 
example, weight and fat control, avoid overdoses of vitamin A, optimizing folate and iodine, 
abstinence from alcohol and other drugs. In addition to this, women with pre-gestational 
diabetes should plan their pregnancy carefully, in order to be able to adjust the diet to 
maintain optimal blood glycemic level, to achieve appropriate maternal weight gain, maintain 
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nutritional health status and to support a healthy pregnancy and optimal growth and 
development for the baby (37). Proper surveillance, metabolic control, and good obstetric care 
can reduce the adverse effects of diabetes on pregnancy outcome in diabetic patients (38).  
1.5.2 Diabetic pregnancy & Diet 
The Norwegian Directorate of Health recommends pregnant women with DM to have a diet 
with a low glycemic index, consuming multiple and regular meals, distributing carbohydrate 
intake evenly between meals, and limiting the intake of sweet foods and beverages. The 
glucose increase after a meal primarily depends on the amount and quality of the 
carbohydrates in the meal. Pregnant women with DM are recommended to take at least 175 
grams of carbohydrate per day (IOM 2007). The dietary tips are adapted to the woman's BMI 
and recommended weight gain (39).   
The diabetic mother can eat healthy food without sugar. Daily food intake will be divided at 
least 4 - 5 meals per day. Mother can take brown bread, drink milk daily, and spread over 3 
meals. High intake of vegetarian foods such as whole grain, legumes, corn, peas, lentils, 
carrots, broccoli, cauliflower, paprika, lettuce, cucumber, and fresh fruits. DM mothers can 
eat up to 3 fruits per day at 1 fruit at a time. Low glycemic fruits are a better choice such as 
blueberries, strawberries. Fish, trimmed meat, chicken, and low intake of processed animal, 
fatty foods and limit the use of salt in food preparation are fine.  It is advisable to substitute 
vegetables or brown bread instead of large amounts of rice, potatoes, spaghetti, and pasta. It is 
better to restrict artificial sweeteners in food (40,41). Fish contain rich omega 3 fatty acids, 
vitamin D, iodine & selenium, these are essential for fetal brain development. Eating fish at 
least 2 to 3 times a week is advisable (42). The increased intake of dietary fiber during 
pregnancy has many benefits to the pregnant woman including lowering the risks of diabetes 
& association with lower daily insulin requirements, reducing risks of preeclampsia, and 
preventing constipation (43). If diabetic women are overweight or obese, they should restrict 
high saturated fatty acid-containing foods like butter, cheese, ghee, meat fat of pork, lamb, 
processed meats like salami, sausages, and hard margarine (40,41). 
In recent years, there was a lot of focus on the importance of the pre-conceptional period, and 
it is now clear that nutrition before pregnancy is associated with maternal, neonatal, and long-
term child health (4). This is especially important to women with diabetes. Nutritional status 
of women is a deciding factor of embryonic and fetal growth at conception. In diabetic 
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women nutritional status and metabolic control are important during this period. Most of the 
fetal organs form between 3 to 7 weeks of pregnancy (10). 
Diet should play a central role in the treatment of pregnant women with pre-gestational 
diabetes however, there are only a few studies that investigated dietary intake during 
pregnancy in women with pre-gestational diabetes, and most recommendations are so far not 
specific for women with diabetes, but are similar to the recommendations given to all 
pregnant women. 
1.6 Measuring dietary intake:    
   Measuring dietary intake is not an easy task, and different methods are available, which 
have their disadvantages and advantages. Information on dietary intake can either be 
prospective (e.g. by food diaries or records) or retrospective (e.g. food frequency 
questionnaires 24 h recalls). Especially the retrospective methods rely on memory and the 
compliance of the participant (45). 
1.6.1 24-hour dietary recall 
This is a dietary assessment tool that contains a structured interview in which participants are 
asked to recall all food and drink they have consumed in the previous 24 hours. 
An advantage of this method is that dietary information can be easily obtained. A single 24-
hour recall is not enough to express an individual’s usual intake of food and nutrients. 
Multiple single days recalls on different individuals can show a valid measure of the intake of 
a group or population. The success of the 24 hours recall depends on the subject’s memory, 
cooperation, and communication ability, the ability of the subject estimates of portion size 
consumed, the degree of motivation of the participant, and the persistence of the interviewer. 
Repeated 24 hours recall should reflect different seasons of the year to estimate the average 
food intake of individuals a longer period. The repeated 24-hour dietary recall is useful for 
assessing the average usual intake of a large population. It is used international comparisons 
of the relationship of nutrient intakes to health & susceptibility to chronic diseases. (45) 
1.6.2 Dietary records or food diaries 
This is typically obtained for 3 or 4 days. It is a prospective, open survey method gathering 
data about the foods consumed over a previously specified time (46). For the estimated food 
record, the respondent is asked to record, at the time of consumption, all foods and beverages 
eaten, either as weight or measured in household measures. Method of preparation and 
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cooking is usually also recorded. Disadvantages include that the quality of the record can be 
declined with increased recorded days. and that the process of recording food intake can lead 
to a change in food intake. The registration of the foods consumed will minimize the problem 
of food omissions due to memory failure. Dietary records are usually considered as a 
reference method in validation studies. (45)  
1.6.3 Food frequency questionnaire (FFQ) 
FFQ consists of a list of foods and drinks with response categories to indicate the usual 
frequency of consumption over the period queried. The FFQ aims to assess the frequency with 
which food items are consumed during a specified period. It is originally designed to provide 
descriptive qualitative information about the usual food consumption patterns. FFQ is 
designed to obtain qualitative, descriptive data on the usual intakes of foods over a long 
period. FFQ must be culture specific. It is less suitable for pregnant women as pregnancy may 
lead to dietary changes, although it has been used in large cohort studies of pregnant women, 
e.g. the Norwegian Mother and Child Cohort Study (MoBa) (45,105). 
1.7 Assessment during pregnancy 
Nutritional status is defined as an individual's health status as it is influenced by the uptake 
and usage of nutrients. Optimal nutritional status is described as consuming enough, but not 
excessive, sources of energy, essential nutrients, and other dietary components such as fiber, 
not containing toxins or contaminants (47). 
Different methods are available for measurement of nutritional status. Measurement of dietary 
intake is one option to assess nutritional status. Other assessment methods include 
anthropometry, biochemical measurements, and clinical assessment.  
In Pregnancy, it is important to monitor nutritional status as this has implications for both 
mother and fetus. Pregnancy is a demanding situation to maintain nutritional status. In most 
cases, normal ranges or reference ranges will be changed due to the metabolic changes in 
pregnancy. There are norms for adequate gestational weight gain, depending on maternal pre-
pregnancy BMI and changes in biochemical measurements due to pregnancy (e.g. the 
physiological anemia of pregnancy)  
1.7.1 Anthropometrics methods 
These are a series of quantitative measurements and useful to assess the size, proportions, and 
compositions of the human body. The core elements of anthropometry are height or 
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recumbent length, weight, body mass index (BMI), circumferences (waist, hip, head, and mid-
upper arm), and skinfold thickness. It is safe, non-invasive, easy to obtain, relatively low cost 
and the calculation is simple. Disadvantages include its low sensitivity and dependency on 
scoring. (48) 
BMI is a commonly used index of nutritional status and a gauge of malnutrition in children 
and adults. Body mass index (BMI) is a simple index of weight(kg) for height (m), it is 
commonly used to classify underweight, normal weight, overweight, and obesity. BMI is 
defined as the weight in kilograms divided by square of the height in meters. 
Underweight:<18.5 kg/m2, Normal weight :18.5-24.9 kg/m2, Overweight: 25-29.9 kg/m2, 
Obesity (grade 1): 30- 34.9 kg/m2, Obesity (grade 2): 35- 39.9 kg/m2 , Obesity (grade 3): ≥ 40  
kg/m2     ( Nordic Nutrition Recommendations – 2012 ,(78)).   
BMI values in adults are age independent & the same for both sexes. In pregnancy, the pre-
pregnancy BMI is important for the recommendations for weight gain. The pre-pregnancy 
BMI distribution in Norway in 2018 was underweight 3.8%, Normal weight 60.8%, 
Overweight 22.7%, Obese 12.7% according to the Norwegian Institute of Public Health (49). 
More than one in three women had overweight or obesity at the beginning of the pregnancy, 
every seventh had obesity (49).   
MUAC is a viable measurement in children or pregnant women as a marker of nutritional 
status. MUAC is the circumference of the left upper arm, measured at the mid-point between 
the tip of the shoulder (acromion process) and the tip of the elbow (olecranon process).  The 
use of MUAC as a predictor of nutritional & health-related outcomes. Even though there are 
significant associations between low MUAC and adverse health outcomes, particularly among 
pregnant women, there was not enough evidence to conclude (50). However, MUAC is 
closely correlated with BMI, and can be used as a surrogate for BMI in patients were BMI 
measurement is not possible. MUAC is an alternative marker to assess women at risk of 
adverse pregnancy outcome in places where weighing is not possible for pregnant women 
(12). 
Skinfolds have been used for body composition calculation before Bioelectrical impedance 
analysis became available. Triceps skinfold is still used, together with MUAC, to calculate the 
mid-upper arm muscle circumference. 
18 
 
Skinfold thickness measurements are easy, simple, and quick to obtain, however in obese 
children accuracy and precision are not reliable. Skinfold equations are population-specific 
but poor accuracy in individuals and groups (51). In pregnancy, skinfold thickness 
measurements can be attained from overweight and obese pregnant women to determine Body 
Fat % and can be utilized in a research site (15). 
Measurement of waist circumference is used to assess the waist and central fat, and these 
measurements are a convenient, quick, and robust measure of abdominal fat and not so 
accurate as a measure of internal visceral fat. Waist circumference is a better indicator than 
BMI and waist-to-hip ratio to detect central obesity, and waist circumference is strongly 
correlated with intraabdominal fat content and cardiovascular risk factors. (51,52). Women 
with small abdominal circumference in third trimester of pregnancy is associated with an 
increased risk of provider preterm delivery (96). 
Bioelectrical impedance analysis (BIA) is a simple, noninvasive, relatively cost-effective, 
easy doing, a painless, quick and commonly used method to estimate body composition 
(quantity of fat mass, fat-free mass), and particularly useful in large epidemiologic studies. 
The method is based on the differences in conductivity of fat mass and fat-free mass of the 
body. A low electrical current is being sent through the body. The method uses the placement 
of dual electrodes (voltage electrodes-black, current electrodes-red) on the person's non-
dominant side of the hand and foot. The device measures how this signal is obstructed 
through different types of tissue. While tissues which contain more fluid and electrolytes have 
high conductivity, fatty tissues are nonconductor of electrical charge. As BIA determines the 
flow resistance when passing current through the body. it provides body water estimation and 
from this, body fat mass can be calculated. Body fat mass is calculated by reducing free fatty 
mass from body weight. Pacemaker users, platinum containing’s object users are not 
advisable to do BIA. It is debated whether BIA can be used in pregnancy. BIA during the 2nd 
trimester of pregnancy are independently associated to the birth weight (79,80). 
1.7.2 Laboratory measurements 
Biochemical tests are used to determine nutrient levels in blood and urine. Serum proteins 
such as albumin and prealbumin are being widely used by clinicians to determine patients’ 
nutritional status. Other serum markers such as retinol-binding protein (RBP), transferrin, 
total cholesterol, and C-reactive protein (CRP) and total lymphocyte count (TLC), 24-hour 
urine creatinine are to be used for estimation of fat-free mass and muscle mass (53). 
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There are many physiological changes occur during pregnancy. These physiological 
alterations in pregnancy result in many significant changes in laboratory test values. Some of 
these changes are, such as the reduction in hemoglobin levels, which is the physiological 
anemia of pregnancy. Similarly, the renal alterations leading to lower creatinine values in 
pregnancy. 
1.7.3 Clinical evaluation 
There is a limited number of tools used for the assessment of nutritional status. The most-used 
tool is the Subjective global assessment (SGA), which is a clinical technique that assesses 
nutritional status based on features of the history and physical examination and scores patients 
on a scale ranging from well-nourished to severely undernourished. SGA is being well-
validated in a variety of patient populations. SGA can easily be trained to a variety of 
clinicians and this technique is reproducible. clinical examinations are used to detect signs of 
nutritional problems. (54) 
1.8 Pre-gestational diabetes and glycemic control during pregnancy 
The goal of medical management of pre-gestational diabetes is to maintain maternal blood 
glucose levels within normal limits throughout pregnancy. It is the aim to achieve good 
glycemic control before conception and maintain through pregnancy and postpartum. 
Glycemic control during pregnancy is assessed by frequent daily self-monitoring of blood 
glucose and periodic measurement of HbA1c. Blood glucose level is maintained through 
adjustments of diet and insulin therapy. Insulin requirements during the first trimester of 
pregnancy are like those prior to pregnancy in women with type 1 diabetes. Dosing is 
continually adjusted based on self-monitoring of blood glucose and HbA1c results (55). 
HbA1c is the result of an irreversible non-enzymatic binding of glucose to plasma proteins, 
specifically hemoglobin (Hb). HbA1c test reflects the average level of blood sugar over the past 
8 to 12 weeks. It is also called glycated hemoglobin test. Glucose in the blood binds with 
hemoglobin in red blood cells. So, the HbA1c test measures how much glucose is bound. Since 
red blood cells live for about 12 weeks, the test shows the average level of glucose in the blood 
for the past 12 weeks. (56). A major advantage is that this test can be done at any time of the 
day and does not need any special preparation such as fasting or dietary preparation. HbA1c 
level can be affected by a variety of genetic, hematologic illnesses. The most common factors 
affecting HbA1c levels are hemoglobinopathies, chronic anemia (iron deficiency, B12 
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deficiency), chronic kidney disease (uremia), hemolysis, and accelerated red blood cell 
turnover (erythropoiesis), for example malaria (57). The HbA1c range is usually lower in 
pregnancy because of the physiologic expansion of the red blood cell mass, iron deficiency 
and decreased erythrocyte life span in pregnancy. Therefore, pregnancy itself reduces HbA1c 
levels, HbA1c targets are lower in pregnant women with diabetes compared with nonpregnant 
women with diabetes (55).  The normal range of HbA1c is 4.7–6.3% in nonpregnant women, 
4.5– 5.7% in early pregnancy, and 4.4–5.6% in late pregnancy (58). 
1.9 Pregnancy complications  
Pregnancy complications are health-related problems that occur during pregnancy. Common 
maternal complications in diabetic pregnancy are miscarriages, abnormal gestational weight 
gain, preeclampsia, polyhydramnios, preterm delivery, stillbirth, hypoglycemia, hypertension, 
deterioration of retinopathy, nephropathy, neuropathy & increased risk for caesarian section 
delivery. Common fetal complications in diabetic pregnancy are excessive fetal growth 
(macrosomia), premature birth, neonatal hypoglycemia, congenital abnormalities, and 
intrauterine growth retardation. 
Regular monitoring during pregnancy allows early detection of health-related problems that 
could arise in pregnancy and their treatment. It will give increase the chance to have a normal 
pregnancy and the birth of a healthy baby.  
(a) Gestational weight gain can be described as weight gained between conception and just 
before the birth of the infant. Weight gain during pregnancy is not only important for this 
pregnancy but also important for the long-term health of mother and baby. 
 Energy intake requirements in pregnancy are used for resting metabolism, diet-induced 
thermogenesis, and physical activity, maternal and fetal growth in pregnancy and thus equals 
to energy expenditure plus energy storage. Resting metabolic rate increases during pregnancy 
due to pregnancy-related physiological demands. The change depends on changes in body 
weight and composition, heart rate, stroke volume, cardiac output, thyroid hormone, insulin-
like growth factor1, and is related to fetal growth & development. The requirement of energy 
storage depends on pre-pregnancy BMI. This difference decides the energy intake 
requirements of pregnant women (59,60). 
The weight gain recommendations are inversely proportional to pre-pregnancy BMI, 
therefore, allow for more weight gain for women who were underweight before pregnancy. 
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The recommended weight of these women is 12.5–18 kg. For women of normal weight, the 
recommended amount of weight gain during pregnancy is 11.5 to 16 kg, and weight gain for 
women who are classified as overweight is 7–11.5 kg and for 5-9 kg to obese, according to 
the 2009 Institute of Medicine guidelines (59,61,78). Average gestational weight gain in 
Nordic countries is between 14 -16.5 kg (78).  Gestational weight gain depends on pre-
pregnant body mass index, hereditary factors, diet pattern, socio-economic status, smoking, 
and physical activity (62). 
Gestational weight gain above or below the recommended range is a serious obstetric 
problem. The prevalence of inadequate gestational weight gain varies among races and 
populations. Health risks related to inadequate weight gain during pregnancy involve a greater 
risk of premature birth and a low birth weight baby and an increased risk of mortality and 
morbidity (64). Excess weight gain is indicated as a risk factor for giving birth to a high birth 
weight baby compared with its gestational age, giving birth to a baby with macrosomia, 
gestational diabetes, pregnancy-induced hypertension (preeclampsia), cesarean section, 
mother’s obesity later in life (62). Early pregnancy weight gain is associated with an increased 
risk of GDM (41).  
(b) Pre-eclampsia is a serious condition that may threaten the life of both mother and child. 
The cause of pre-eclampsia is unknown; however, the cure occurs after delivering the 
placenta. Preeclampsia is characterized by high blood pressure and albuminuria. It is defined 
as systolic blood pressure is equal or more than 140 mm Hg or diastolic blood pressure is 
equal or more than 90 mm Hg on two occasions at least four hours apart in the second half of 
pregnancy in a previously normotensive woman and proteinuria (equal or more than 300 
mg/24 hours). The probability of having pre-eclampsia is increased to the women who have a 
previous history of pre-eclampsia, diabetes mellitus, hypertension, obesity, multiple 
pregnancies, and women who are more than 40 years old. Pre-eclampsia is occurring in 3-5 % 
of normal pregnancies, and diabetic women have a higher risk of pre-eclampsia 
(65).  Preeclampsia risk is 2 to 4-fold higher in type 1 or type 2 diabetes mellitus. Women 
with type 1 DM complicated with preeclampsia have an increased risk of retinopathy and 
nephropathy (66).  
(c) Birthweight is another outcome of interest. In Norway, the average birth weight between 
2003 and 2006 was 3710 g in boys and 3580 g in girls according to Bergen's growth study 
22 
 
(67). When comparing birth weights, it is important to adjust the birth weight according to 
gestational age, as the weight of the fetus is increasing during the last weeks of pregnancy.  
Macrosomia is defined as birth weight is more than 4,000 g irrespective of gestational age 
or above the 90th percentile which is corrected for gestational age, sex, and parity. It affects 
3-15% of all pregnancies in the population (68). Macrosomia causes some delivery 
complications for both mothers and babies. There are some factors associated with fetal 
macrosomia such as genetics, duration of gestation, diabetes mellitus, obesity, multiparity, 
and ethnic factors (69). Macrosomia is associated with increased risk for being overweight or 
obese in later life (108). Women with DM have high blood glucose, the baby gets too much 
glucose through the placenta, baby’s pancreas senses it, and resulting hyperinsulinemia. 
Hyperinsulinemia stimulates the storage of glycogen in the liver and increased the production of 
adipose tissue. Insulin is a growth factor and leads to accelerated fetal growth.  
Instead of absolute values of birth weight, often z scores are used  
The z score is a very useful statistic that helps us to find the probability of a score occurring 
within normal distribution and make it possible to compare two scores which are from 
different normal distributions. 
The Z-score system shows the anthropometric value as several standard deviations or Z-
scores below or above the reference mean or median value (70). For z scores for birth weight, 
data as gestational age, and sex of child are considered.  
(d) Neonatal hypoglycemia is defined as blood glucose is equal or less than 2.6 mmol/l or 47 
mg/dl and severe neonatal hypoglycemia as blood glucose are equal or less than 2.0 mmol/l in 
a neonatal baby. Neonatal hypoglycemia is the most common metabolic problem in neonates. 
The incidence of neonatal hypoglycemia is 25% of all deliveries in the first 48 hours of life in 
neonates above 35 weeks gestation. After clamping of the umbilical cord, neonates blood 
glucose declines in the first hours of life. For healthy neonates, hypoglycemia is brief and 
transient. Prolonged hypoglycemia may occur due to insufficient glucose supply, inadequate 
glycogen storage, or increased glucose usage due to excessive insulin production or increased 
metabolic demand (71). Glucose is a vital source of energy required continuously by the 
infant. Neonatal hypoglycemia can cause long term neurological and developmental 
consequences. Low birth weight babies, large for gestational age babies, infant of diabetic 
mothers are prone to get neonatal hypoglycemia (71,72).   
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(e)  A preterm/premature baby is defined as a baby born alive before 37 weeks of gestation 
(74). Approximately 15 million babies are born as premature and preterm complications are 
leading cause of death among under 5 years of children. Preterm birth can be subcategorized 
based on gestational age as, extreme preterm (less than 28 weeks of gestation), very preterm 
(28-32 weeks), moderate to late preterm (32-37 weeks). Approximately 1in 10 babies are born 
as preterm, and many survivors are living with a disability, learning difficulties, and visual & 
hearing problems (75,76). Common causes of preterm are multiple pregnancies, diabetes, high 
blood pressure, infections, and unknown reasons (75). A study which took place in Israel 
indicates that the prevalence of spontaneous preterm delivery was 7.1% in non-diabetics, 
10.0% in with gestational DM, and 25.5% in those with pre-gestational DM (77). 
1.10 Study aims and hypothesis 
This thesis is part of a larger study that had the aim to investigate the effect of metabolic 
control in women with pre-gestational diabetes on the development of the fetus and the birth 
outcomes. This thesis will focus on diet in women with pre-gestational diabetes and on 
associations with metabolic control in the women and birth outcomes such as macrosomia, 
and prematurity. In addition to these dichotomous outcomes, the continuous outcome 
variables z score of birth weight and gestational age at birth are used. 
1.11 Objectives 
The goal of the study is to determine the association of diet during pregnancy in women with 
pre-gestational diabetes with pregnancy outcomes. 
• To investigate the association of diet, metabolic control, and pregnancy outcomes z 
score of birth weight and macrosomia. 
• To investigate the association of diet, metabolic control, and pregnancy outcomes 









2. Patients and Methods  
2.1 Study design 
This study is part of a larger project (the DiaDoppler study). the DiaDoppler study is a 
prospective longitudinal observational study (follows the same subjects repeatedly over a 
period) of women with pre-gestational diabetes. The study is conducted in collaboration with 
“the research group for pregnancy, fetal development, and birth” at Obstetrics and 
Gynecological Department of Haukeland University Hospital (A.Lund MD PhD).  
The study protocol was approved by the regional committee for Medical Research Ethics 
(REK vest 2011/2030). The participants were provided with oral and written information in 
detail about the study and 52 women gave written consent. Three participants withdrew after 
1st prenatal visit. Participation was voluntary and the women could withdraw from the study at 
any time. Participants could send feedback by email if they want, anytime during the study 
period. 
This study was carried out at the Department of Obstetrics and Gynecology, Haukeland 
University Hospital. DiaDoppler monitor maternal health status, fetal development, and fetal 
circulation in diabetic pregnancies. This study includes ultrasound scanning every fourth 
week of pregnancy and takes several fetal measurements such as fetal heart rate (CTG-
cardiotocography), fetal circulation, biometrics, etc. Anthropometric measurements, blood 
samples, and body composition of the diabetic pregnant women were done, and 
measurements during and after birth.  
2.2 Study Population 
The study population consists of pregnant women with pre-gestational diabetes who received 
prenatal health care at Haukeland University Hospital, Bergen. The study period was between 
August 2013 and May 2016. 
2.2.1 Recruitment 
 Women with pre-gestational diabetes in Hordaland county were referred to Haukeland 
University Hospital as soon as pregnancy was diagnosed. All women with PGDM at the 
hospital received study information by mail and based on the inclusion and exclusion criteria 
were asked to participate during their first prenatal visit at Obstetrics and Gynecological 
Department of Haukeland University Hospital (n=82). They were informed thoroughly about 
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the study and consequences by A.Lund MD PhD. In addition to this, there was information 
about the study on the internet home page of Haukeland University Hospital. 
Inclusion criteria were pre-gestational diabetes and singleton pregnancies. The exclusion 
criteria were multiple pregnancies, diabetes due to other than type1or type2 and inability to 
understand the English or Norwegian language. If abortion occurred, they would have been 
excluded automatically. 
 
Figure 2 Inclusion of participants in the study (Flow chart) (110) 
 
Finally, 49 women were included in the study. Out of these 49 participants, 44 women had 
type 1 DM, and 5 had type 2 DM. Three women with Type I DM participated in two 
consecutive pregnancies. All participants used insulin treatment during pregnancy.  
Participants self-declared their ethnic identity, in the Type1 DM 39 were Norwegian, 4 from 
other European countries and one Norwegian with parents from Chile. In the Type2 DM, one 
was Japanese American, one Chilean Norwegian, one from the Philippines, and two 




2.2.2 Measurements  
At the first visit, basic and health information was collected such as age, parity, ethnicity, 
blood group, education, occupation, duration of diabetes, diabetic complication, medication, 
alcohol  
Consumption, smoking habits, other diseases, past and present obstetric history, and family 
history of diabetes.  
The following measurements were made at baseline and throughout the pregnancy and were 
used to describe the study population: 
Mother 
• weight, height, BMI, waist, and mid-arm circumference 
• Bioelectrical impedance analysis (by Tanita) (weight, fat mass, muscle mass) 
• HbA1c: - Mean HbA1c of each trimester was calculated from all available 
measurements (which were individual for each women). The frequency of attendance 
of the women was different, and therefore a mean HbA1c was calculated from all 
visits in a respective trimester of pregnancy. 
• Dietary intake of energy, macronutrients added sugar and fiber as measured by 3day 
dietary records. 
2.3 Pregnancy outcome  
            In the current analysis, the following outcomes of interest were analyzed. 
           Infant birth weight: Health personnel measured neonatal birth weight by standard 
methods at the maternity ward. Macrosomia was defined as birth weight by gestational age 
 ≥ 97.5th percentile for a Norwegian population (73) A z-score using birth weight, gestational 
age, and sex, were calculated, where macrosomia corresponds to Z score > 1.96. 
           Gestational age at birth was calculated either based on early ultrasound (Crown Rump 
Length) or the date of the 1st day of last menstrual period.   
          Preterm delivery is defined as a baby born alive before 37 weeks of gestation. 
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Figure 3 Flow chart of data collections at different stages (13) 
Dietary data were collected three times during pregnancy such as around gestational weeks 
9,28, and 36. Patients had ultrasound scanning at gestational week 9,20,24,28,32, and 36. 
Anthropometrical measures, biological impedance analysis, and blood samples, 3 days food 
record were done at gestational weeks 9,24and 36. 
The dietary assessment method used in this study was three days of food records. Food 
records were taken for 3 consecutive days, including two weekdays and one weekend day. 
Participants got instructions on how to do 3 days of food recording.  
The Participants were instructed to record intake of all food and beverages, and were asked to 
preferably weigh the food, otherwise, use household weights and measures. Participants were 
asked to register the label of groceries and the recipes of homemade cooking, together with 
the amount eaten of every meal.  
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They were specifically asked to record food ingested to monitor blood glucose, use of vitamin 
and mineral supplementation should also be recorded. Completed dietary registrations were 
put in prepaid envelops and returned to the study center or brought back to the next study 
visit. 
Each study visit, blood sample was taken for the HbA1c test. Results were obtained from the 
Clinical Biochemistry Laboratory at Haukeland University Hospital. 
Pregnancy outcome was recorded at each control and information of neonate sex, mode of 
delivery, birth weight, length, head circumference, waist & arm circumferences, Apgar score, 
and other maternal and neonatal complications were collected from clinical records at 
Obstetrics and Gynecological Department of Haukeland University Hospital. 
2.4 Data analysis 
Dietary intake analysis  
The food records of participants were “3 days” food intake records of each participant of each 
trimester were analyzed by using “kostholdplanleggeren” (kostholdsplanleggeren.no) (63), a 
tool made for the calculation of nutritional contents of foods from the Norwegian Directorate 
of Health. The dietary intake of macronutrients of each participant was calculated manually 
both in grams and as a percentage of total energy intake.   
2.5 Statistical analysis 
Collected data were analyzed with statistical package for the social sciences software (SPSS 
version 24). The results were expressed as mean, standard deviation, median and interquartile 
range, or as number, percentage, and frequency. As only a subgroup of women submitted 
dietary information, these were first compared to the entire study group. Within the women 
who submitted dietary data, the outcomes “macrosomia” and “prematurity” were analyzed. 
Dietary data from each trimester and dietary changes from 1st to 2nd to 3rd trimester were 
compared by non-parametric tests for independent variables. 
Further, correlation analysis using spearman rank correlation of dietary data of each trimester 
and the continuous variables “z score of birth weight” and “gestational age at birth” was 
made.  





Data from 49 women were available throughout pregnancy, and of these, 26 submitted dietary 
data during 1st trimester (Table-1). Out of 49 women, 44 (90%) women suffered from Type 
1DM, and 5 (10%) women suffered from Type 2DM. The median duration of diabetes was 17 
years. Of these 49 PGDM women, 20 were nulliparous and 29 were parous 1+. The average 
maternal age was 30±4 years which was comparable with the average age of women giving 
first birth in Norway in 2018 (29.5 years). The median admission time to the study was at 9.4 
weeks gestational age. The median Pre-pregnancy weight was 70 kg. The mean pre-
pregnancy BMI was 26.8 ± 5.4 kg/m2 in this study.  
3.1 Table 1: Maternal & neonatal characteristics of the final study population 
 All women (n=49) Women with dietary data in 1st 
trimester (n=26) 
 Mean ± 





Mean ± SD 
or N (%) 
Median (25th to 75th 
percentile) 
Diabetes mellitus type1                   44 (90%) 24 (92%) 
Diabetes mellitus type2                    5 (10%)  2 (8%) 






                       3 
                      22 
                      20 
Not available  
Parity 0 





Gestational age at inclusion, 
week 
10.2 ± 2.6 9.4 (8.5,11.1) 10.2 ± 2.5 9.7 (8.8, 11.1) 
Weight (pre-pregnancy), kg 
n=44 




Height, cm 167 ± 6 168 (162, 
171) 
166.6 ± 5.6 167 (162,171) 
BMI (pre-pregnancy) 26.8 ± 5.4 25.4 
(22.8,29.2) 
26.0 ± 4.2 25.1(23,28.9) 




- Hypothyroidism 9 (18%) 5 (19%) 
- Hypertension 7 (14%) 3 (11.5%) 
- Retinopathy 9 (18%) 4 (15.4%) 
- Nephropathy 1 (2%) 0 
Table 1: Maternal & neonatal characteristics of the final study population. 
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Results for those women who provided dietary data at 1st trimester: - 26 of 49 returned “3 
days” food record from 1st trimester (53%), 24 during 2nd trimester,19 during 3rd trimester. 
Out of 26 women who provided dietary data at 1st trimester, 24 (92%) women suffered from 
type 1DM, and 2 (8%) women suffered from Type 2DM. The average maternal age was 29.4 
± 4.5 years. The median Pre-pregnancy weight was 67.5 kg, the mean pre-pregnancy BMI 




























3.2 Table 2: Characteristics of pregnancy and birth 
 
In all women, mean gestational age at birth was 37.8 ± 2.6 weeks, and the boys to girl's birth 
ratio was 1.04 /1, which almost resembles the Norwegian population birth ratio (1.07/1). 
Mean birth weight was 3591± 892 g, Cesarean birth was 45 % of all births. Premature birth 
was 31 % in this study group, Perinatal death occurred in one pregnancy, 4 % (n=2) of babies 
were born with a congenital malformation. 40% of babies were transferred to the intensive 
neonatal unit after birth. 
Results from women who provided dietary data in 1st trimester were very similar to the entire 





 All women Women with dietary data in 1st 
trimester.  
Mean ± SD 
or N (%) 
 
Median (25th to 
75th percentile 
Mean ± SD 
or N (%) 
Median (25th to 
75th percentile 
Gestational age (birth)  37.8 ± 2.6 38.6 (36.7,39.6) 38.1 ± 2.1 38.8 (36.7, 39.6) 
Preeclampsia                       3 (6%) Not available 
Preterm birth 15 (31%) 7 (28%) 
Induction of labor 30 (60%) 14 (56%) 
Normal vaginal delivery 20 (40%) 4 (16%) 
Operative vaginal 
delivery  
 7 (14%) 7 (28%) 
Cesarean section  22 (45%) 14 (56%) 
- elective 9 (41%) Not available 




Sex (male/ female)                     25/24                      10/16 
Birthweight (g) 3591± 892 3695 (3150,4150) 3626 ± 697 3690 
(3228,4138) 
Birthweight Z score 1.05 ± 1.70  0.9 (0.1,2.0) 1.04 ± 1.43 0.97 (0.2, 2.0) 
Transfer to an intensive 
neonatal unit 
20 (40%) Not available 
Perinatal death 1(2%) 
Malformation 2 (4%) 
Table 2: Characteristics of pregnancy and birth. 
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3.3 Table 3: Anthropometric measurements and HbA1c of the women during 
pregnancy  
 All women  Women with dietary data in 1st 
trimester  




















kg 85 ± 14 82 (76,91) 83 ± 15 
(n=23) 
80 (75, 85) 
Weight 3rd 
trimester(n=40) 





cm 32 ± 5 31 (29,36) 31 ± 4 
 (n= 25) 
30 (29, 33) 
MUAC 2nd 
trimester(n=42) 
cm 33 ± 4 32 (30,36) 32 ± 3 
(n = 23) 
32 (30, 33) 
MUAC 3rd 
trimester (n=39) 
cm 33 ± 4 32 (30,35) 32 ± 4 
(n= 22) 
32 (30, 34) 
Waist 1st trimester 
(n=47) 
cm 93 ± 15 91 (82,99) 91 ± 12 
(n= 25) 
91 (82, 97) 
Waist 2nd trimester 
(n=42) 
cm  106 ± 12 104 (98,112) 104 ± 11 
(n = 23) 
103 (98, 107) 
Waist 3rd trimester 
(n=39) 
cm  113 ± 12 111(105,120) 112 ± 12 
(n= 22) 
112 (104, 118) 
HbA1c 1st trimester % 6.7 ± 0.7 6.5 (6.0, 7.0) 6.5 ± 0.6 6.5 (6.0,6.9) 
HbA1c 2nd 
trimester 
% 5.9 ± 0.6 5.9 (5.5,6.3) 5.8 ± 0.6 5.9 (5.3,6.3) 
HbA1c 3rd 
trimester 
% 6.0 ± 0.6 6.0 (5.6,6.5) 6.0 ± 0.6 6.1 (5.3,6.5) 
Table 3: Anthropometric measurements and HbA1c of the women during pregnancy. 
MUAC- Mid upper arm circumference, Waist C-Waist circumference, HbA1c - Glycated hemoglobulin 
concentrations 
Pre- gestational BMI  (n=49) revealed that 49% of them were normal weight (n=24), 28%   
were overweight (n=14), and 22% were obese (n=11), and these figures were similar in 
women who provided dietary data at 1st trimester (13 women normal weight (50%), 8 women 
(30%) overweight, and 5 women (20%) were obese).  
The mean glycated hemoglobin test (HbA1c) among those with dietary data at 1st trimester 
showed that 12 women (50%) had less than 6.5% and 12 women (50%) had more than 6.5 %. 
















































3.4 Table 4: Dietary data of the women with PGDM 
 Trimester 1 (n=26) Trimester 2 (n=24) Trimester 3 (n=19) 
 Mean (SD) or N (%) Median (25th to 
75th percentile) 
Mean (SD) or N 
(%) 
Median (25th to 75th 
percentile 
Mean (SD) or N 
(%) 
Median (25th to 
75th percentile 
Energy (kcal/d)   2102 ± 410 2129 (1773, 2378) 2174 ± 447  2125 (1821, 2458)  2300 ± 662 2352 (1734, 
2766) 
Protein (g/d)  
energy % 
90 ± 20 
17.0 ± 3.7 
91 (72, 106) 
16.4 (14.7, 19.8) 
95.8 ± 20.5 
17.8 ± 2.9 
94 (77, 111) 
17.8 (16.6, 20.1) 
101 ± 33 
17.0 ± 2.6 
100 (78, 122) 
17.7 (15.0, 18.8) 
Fat (g/d) 
energy % 
81 ± 21 
34.5 ± 6.6 
84 (65, 102) 
34.5 (29.5, 37.8) 
89 ± 23 
36.7 ± 5.0 
86 (76, 95) 
37.0 (33.0, 41.0) 
89 ± 32 
35.0 ± 6.0 
87 (70, 107) 
35.0 (31.0, 40.0) 
Carbohydrate (g/d) 
energy % 
242 ± 67 
45.8 ± 8.6 
257 (200, 279) 
46.0 (40.9, 51.6)  
236 ± 65 
43.0 ± 6.7 
225 (186, 276) 
43.0 (38.0, 47.0) 
259 ± 85 
45.0 ± 6.9 
230 (187, 338) 
45.6 (39.0, 49.0) 
Added sugar (g/d) 
energy % 
38 ± 23 
7 ± 4.3 
39 (18, 54) 
8 (3.5, 9.6) 
37 ± 22 
6.6 ± 3.4 
37 (16, 51) 
6.5 (3, 8.7) 
38 ± 29 
6.6 ± 4.7 
33 (11, 68) 
5 (2,11) 
Dietary fiber (g/d)  25.6 ± 9.0 26.0 (17.5, 31.5)   24.6 ± 8.0 22.0 (17.0, 31.0) 29.0 ± 11.0 26.0 (20.0, 33.0) 
SFA (g/d) 31.0 ± 8.7 31.5 (23.5, 37.3) 34.8 ±9.9 34.0 (31.0, 39.0) 32.6 ± 11.0 31.0 (26.0, 41.0) 
tFA (g/d) 0.7 ± 0.5 1.0 (0, 1.0) 0.9 ± 0.5 1.0 (1.0,1.0) 0.8 ± 0.5 1.0 (1.0, 1.0) 
MUFA (g/d) 28.7 ± 8.9 29.5 (21.0, 35.0) 30.0 ± 9.0 29.0 (25.0, 34.0) 33.0 ± 14.0 32.0 (24.0, 39.0) 
PUFA (g/d) 12.0 ± 4.0 12.0 (9.0, 15.0) 14.9 ± 7.5 13.5 (10.0, 15.0) 14.6 ± 8.0 13.0 (10.0, 18.0) 
Omega 3 fatty 
acids (g/d) 
3.0 ± 1.3 3.0 (2.0, 4.0) 3.3 ± 2.0 2.5 (2.0, 4.8) 3.0 ± 1.8 3.0 (2.0, 5.0) 
Omega 6 fatty 
acids (g/d) 
9.3 ± 3.7 10.0 (6.0, 11.0) 11.5 ± 5.8 10.0 (8.3, 12.0)  11.0 ± 6.4 10.0 (7.0, 14.0) 
Cholesterol (mg/d) 286 ± 134 284 (174, 367) 309 ± 184 247 (205, 367) 303 ± 136 277 (195, 405) 
Table 4: Dietary data of the women with PGDM. 
 SFA- saturated fatty acids, MUFA - monounsaturated fatty acids, PUFA - polyunsaturated fatty acids, E%- energy percentage, Omega 3 FA - Omega 3 fatty acids, Omega 6 
FA Omega 6 fatty acids  
Participants handed over a “3 days” food record from the first trimester (53%), from the second trimester (49%), from third trimester (39%). 
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Total mean energy intakes in the 1st, 2nd, and 3rd trimester were 2102, 2174, and 2300 kcal, 
respectively. Total carbohydrate intake was 45 E% in the 1st and 3rd trimester, and 43 E% in 
2nd trimester. Total protein intake was 17 E% throughout the pregnancy. Total fat intake was 
35 E% in the 1st and 3rd trimester, and 37 E% in 2nd trimester. 
 
Total added sugar intake was 6-7 E% throughout the pregnancy. 
 
Total intake saturated fatty acids (SFA) were 13.3 E% in 1st trimester, 14.4 E% in 2nd 
trimester, and 12.8 E% in 3rd trimester. Total intake of monounsaturated fatty acids (MUFA) 
was 12.3 E% in 1st trimester, 12.4 E% in 2nd trimester, 12.9 E% in 3rd trimester. Total intake 
of polyunsaturated fatty acids (PUFA) was 5.1 E% in 1st trimester, 6.2 E% in 2nd trimester, 
and 5.7 E% in 3rd trimester. 
 
The average intake of dietary fiber was 25-26 g /day in 1st trimester, less than 26 g/day in 2nd 
trimester, and 29 g /day (median 26 g /day) in 3rd trimester. 
 
The average intake of Omega 3 FA was 3 g daily, and the average intake of Omega 6 FA was 


















3.4.1 Table 4.1: Dietary changes during pregnancy 
                      
Table 5.1: Dietary changes during pregnancy. 
Among the women who submitted dietary data, 19 submitted data from both the 1st and the 
2nd trimester, and 15 provided data from the 1st and 3rd trimester (Table 4,2). From 1st to 2nd 
trimester, there was only a marginal increase in energy intake, while the increase was 184 kcal 
per day in the 3rd trimester. For comparison, the Nordic Nutrition recommendation 
recommends an increase of 329 kcal per day in the 2nd trimester an increase of 537 kcal per 















 Change from 1st to 2nd   
trimester (n=19) 
(Mean ± SD)  
Change from 1st to 3rd 
trimester (n=15) 
(Mean ± SD) 
Energy (kcal)        23 ± 370 184 ± 510 
Protein (g/d)        2.5 ± 25.0 12.4 ± 26.9 
Fat (g/d)          4 ± 23    11 ± 25 
Carbohydrate (g/d)          -6 ± 72      9 ± 79 
Dietary fiber (g/d)           -2 ± 7      0 ± 9 
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3.5 Table 5: correlations of dietary intake during pregnancy with pregnancy 
outcomes (z-score of birth weight & gestational age at birth) 
 
Very few significant correlations of dietary intake in 1st trimester with birth outcomes of 
birthweight and gestational age at birth. Of note, dietary fiber was associated inversely with 
birthweight and positively with gestational age at birth. 




1st trimester (n=26) Energy Kcal/d - 0.122 0.14 
 Protein g/d - 0.199 0.025 
 Fat g/d - 0.055 - 0.168 
 Carbohydrates g/d - 0.099 0.082 
 Added sugar g/d 0.062 0.064 
 Dietary fiber g/d - 0.267 0.419 
 Protein E% - 0.037 0.045 




 Added sugar E% 0.167 0.004 
2nd trimester (n=24) Energy Kcal/d - 0.174 0.503 
 Protein g/d - 0.167 0.451 
 Fat g/d - 0.275 0.582 
 Carbohydrates g/d - 0.128 0.272 
 Added sugar g/d - 0.394 0.196 
 Dietary fiber g/d - 0.348 0.512 
 Protein E% 0.051 - 0.025 
 Fat E% 0.058 0.196 
 Carbohydrates 
E% 
- 0.054 - 0.175 
 Added sugar E% - 0.422 0.096 
3rd trimester (n=19) Energy Kcal/d 0.239 - 0.052 
 Protein g/d 0.123 - 0.103 
 Fat g/d 0.185 - 0.059 
 Carbohydrates g/d 0.266 - 0.095 
 Added sugar g/d 0.155 - 0.179 
 Dietary fiber g/d 0.308 - 0.059 
 Protein E% - 0.132 - 0.044 
 Fat E% - 0.116 0.134 
 Carbohydrates 
E% 
0.244 - 0.145 
 Added sugar E% 0.118 - 0.184 




In the 2nd trimester, intake of fat, fiber, added sugar was inversely correlated with birthweight 
and energy, fat, protein, and carbohydrates intake were positively correlated with gestational 
age at birth. 
In the 3rd trimester, intake of energy, carbohydrates, and fiber was positively correlated with 
birth weight and while no correlation was seen with gestational age at birth.  
3.6 Table 6: correlations of maternal factors with pregnancy outcomes 




Pre-pregnancy Weight (kg) 0.007 - 0.048 
 Height (m)           - 0.302 - 0.059 
 Maternal age 0.146 - 0.007 
 Weight gain (kg) 0.382 - 0.024 
 Weight gain /week 0.401 - 0.052 
1st trimester 
(n=26) 
HbA1c (%) 0.429 - 0.427 
 Maternal body 
weight (kg) 
0.165 - 0.181 
2nd trimester 
(n=24) 
HbA1c (%) 0.457 - 0.128 





HbA1c (%) 0.471 - 0.228 
 Maternal body 
weight (kg) 
0.325 -  0.274 
Table 7: correlations of maternal factors with pregnancy outcomes. 
Maternal age and mothers’ pre-gravid weight was positively correlated with birth weight. 
In the 3rd trimester, maternal weight and HbA1c were positively correlated with birth weight. 
Generally, mothers’ weight, Hb1Ac was positively correlated with Z-score birth weight & 









3.7 Table 7: factors related to preterm delivery 






Numbers  34 15  
Maternal age 30 ± 4 29 ± 3 0.437 
Z score birth weight 1.0 ± 1.5 1.2 ± 2.2 0.740 
Gestational age at birth 39 ± 1 34.7 ± 2.8 0.000 
Height (cm) 166.6 ± 5 166.7 ± 8 0.912 
Pre-gravid weight (kg) 75 ± 16 70 ± 9 0.603 
HbA1c % 1st trimester 6.6 ± 0.8 7.0 ± 0.6 0.036 
HbA1c %2nd trimester 5.8 ± 0.6 6.0 ±0.7 0.190 
HbA1c % 3rd trimester 6 ± 0.5 6.3 ± 0.9 0.184 
 n=19 n=7  
Carbohydrate (g/d) 1st 
trimester 
243 ± 69 239 ± 67 1.000 
Carbohydrate (g/d) 2nd 
trimester 
248 ± 67 202 ± 50 0.177 
Added Sugar (g/d) 1st 
trimester 
40 ± 24 33 ± 20 0.497 
Added Sugar (g/d) 2nd 
trimester 
40 ± 23 27 ± 17 0.199 
Dietary fiber (g/d) 1st 
trimester 
28 ± 9 20 ± 6 0.041 
Dietary fiber (g/d) 2nd 
trimester 
26 ± 8 19 ± 7 0.056 
Fat intake 1st trimester 
(g/d) 
81 ± 21 80 ± 24 0.910 
Fat intake 2nd 
trimester(g/d)   
95 ± 22 68 ± 12 0.002 
Protein intake 1st 
trimester (g/d) 
92 ± 19 85 ± 24 0.461 
Protein intake 2nd 
trimester (g/d) 
101 ± 20 81 ± 14 0.027 
Energy intake 1st 
trimester (kcal) 
2122 ± 467 2051 ± 200 0.692 
Energy intake 2nd 
trimester (kcal) 
2306 ± 416 1779 ± 282 0.003 
 n=15 n=4  
Change in energy 
(kcal) intake 1st to 2nd 
trimester 
86 ± 387 -214 ± 173 0.124 
Change in protein (g/d) 
intake 1st to 2nd 
trimester 
8 ± 23 -17 ± 26 0.124 
Change in fat intake 
(g/d) 1st to 2nd trimester 







intake 1st to 2nd 
trimester 
-7 ± 75 -4 ± 67 0.736 
Change in fiber intake 
(g/d) 1st to 2nd trimester 
-3 ± 8 0 ± 4 0.530 
Table 8: factors related to preterm delivery. 
 
Out of 49 deliveries 15 babies were delivered as preterm, and 34 babies were born at term. 
The average gestational age for preterm delivery was 34.7 ± 2.8 weeks. Significant difference 
observed for Hb1Ac in 1st trimester (p-value: 0.036), and non-significantly in the 2nd & 3rd 
trimester also. 
26 mothers submitted diet records in 1st trimester, out of these 19 delivered term babies and 7 
mothers delivered preterm baby. In 1st trimester, the only observed difference was the fiber 
intake. In the 2nd trimester energy, fat, protein intake was significantly lower in preterm 
delivery mothers. 
 Only 19 mothers submitted diet records in 2nd trimester, out of these 15 delivered term babies 
and 4 mothers delivered preterm baby. There were no significant changes in energy, protein, 
and fat intake from 1st to 2nd trimester in mothers who delivered preterm and those who 
delivered at term. 
 
Figure 6. Energy intake in women accounting to prematurity. 




Figure 7. Fiber intake in 1st & 2nd trimester according to prematurity. 




Figure 8. Fat and protein intake in in the 1st & 2nd trimester according to prematurity. 






3.8 Table 8: Macrosomia (women with dietary data: 15 infants without 
macrosomia, 11 infants with macrosomia) 
 No macrosomia 
      (n=30) 
Macrosomia 
       (n=19) 
P value Wilcoxon 
test 
Maternal age (years) 30.2 ± 4.3 29.8 ± 3.8 0.696 
Weight gain (kg) 12.2 ± 5.8 (n = 27) 17.1 ± 6.2 (n = 18) 0.012 
Z score birth weight 0.019 ± 1.0 2.679 ± 1.2 0.000 
Gestational age at 
birth (weeks) 
37.6 ± 3.1 38.1 ± 1.4  0.813 
Height (cm) 166.2 ± 5.5 167.6 ± 6.6 0.530 
Pre-gravid BMI 
(kg/m2) 
26.7 ± 5.9 27.1 ± 4.5 0.320 
HbA1c % 1st 
trimester 
6.5 ± 0.8 6.9 ± 0.6 0.045 
HbA1c % 2nd 
trimester 
5.7 ± 0.7 6.1 ± 0.5 0.061 
HbA1c % 3rd 
trimester 
5.9 ± 0.6 6.3 ± 0.6 0.014 
                                                 Women with dietary data 
Carbohydrate (g/d) 
1st trimester 
250 ± 67 (n = 15) 231 ± 69 (n=11) 0.610 
Carbohydrate (g/d) 
2nd trimester 
249 ± 70 (n=10) 229 ± 57 (n=9) 0.720 
Carbohydrate (g/d) 
3rd trimester 
241 ± 83 (n=8) 279 ± 88 (n=7) 0.357 
Added Sugar (g/d) 
1st trimester 
36 ± 22 (n = 15) 41 ± 24 (n=11) 0.574 
Added Sugar (g/d) 
2nd trimester 
42 ± 24 (n=10) 34 ± 17 (n=9) 0.447 
Added Sugar (g/d) 
3rd trimester 
35 ± 31 (n=8)  41 ± 28 (n=7) 0.669 
Dietary fiber (g/d) 1st 
trimester 
28 ± 10 (n = 15) 22 ± 8 (n=11) 0.134 
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Dietary fiber (g/d) 
2nd trimester 
27 ± 10 (n=10) 22 ± 6 (n=9) 0.243 
Dietary fiber (g/d) 
3rd trimester 
28.8 ± 14.1 (n=8) 29.0 ± 6.6 (n=7) 0.970 
Fat intake (g/d) 1st 
trimester 
86 ± 16 (n = 15) 73 ± 25 (n=11) 0.148 
Fat intake (g/d) 2nd 
trimester 
91 ± 14 (n=10) 83 ± 21 (n=9) 0.356 
Fat intake (g/d) 3rd 
trimester 
91 ± 35 (n=8) 87 ± 30 (n=7) 0.812 
Protein intake (g/d) 
1st trimester 
95 ± 20 (n = 15) 84 ± 19 (n=11) 0.134 
Protein intake (g/d) 
2nd trimester 
98 ± 20 (n=10) 92 ± 18 (n=9) 0.549 
Protein intake (g/d) 
3rd trimester 
100 ± 39 (n=8) 102 ± 27 (n=7) 0.911 
Energy intake 
(kcal)1st trimester 
2207 ± 364 (n = 15) 1960 ± 441(n=11) 0.164 
Energy intake 
(kcal)2nd trimester 
2257 ± 336 (n=10) 2078 ± 369 (n=9) 0.356 
Energy intake 
(kcal)3rd trimester 
2241 ± 677 (n=8) 2364 ± 678 (n=7) 0.698 
 n = 10  n = 9   
Change in energy 
intake (kcal)1st to 2nd 
trimester 
-31 ± 365  83 ± 388 0.437 
Change in protein 
intake (g/d)1st to 2nd 
trimester 
-4 ± 21 10 ± 29 0.447 
Change in fat intake 
(g/d)1st to 2nd  
trimester 





(g/d)1st to 2nd 
trimester 
-7 ± 89 -6 ± 52 0.604 
Change in fiber 
intake (g/d)1st to 2nd 
trimester 
-3.5 ± 7.5 -0.7 ± 6.3 0.400 
Table 9: Macrosomia (women with dietary data: 15 infants without macrosomia, 11 infants with macrosomia). 
Out of 49 deliveries, 19 were macrosomia babies (39%). Gestational weight gain is higher in 
mothers who gave birth to a macrosomia baby (p- value: 0.012).  
 Hb1Ac was higher throughout pregnancy in mothers who gave birth to a macrosomia child.   
1st trimester (p- value: 0.045), 2nd (p- value: 0.061) and 3rd trimester (p- value: 0.014).  
 Among the women who submitted diet records in 1st trimester, 15 delivered non-macrosomia 
babies and 11 mothers delivered macrosomia babies. There was no significant difference in 
the intake of energy, carbohydrate, fat, protein, or fiber between the groups throughout 
pregnancy. 
Among the women who submitted diet records in 2nd trimester, 9 delivered macrosomia 
babies, and 10 mothers delivered non-macrosomia babies. No differences in dietary intake 
between the groups were observed.  
Fiber intake in 1st and 2nd trimester was lower in mothers who delivered macrosomia babies. 
Among the women who submitted diet records in 3rd trimester, 7 delivered macrosomia 
babies, and 8 mothers delivered non-macrosomia babies. No differences in dietary intake 















Figure 11. Pre- pregnancy BMI & gestational weight gain in women who had macrosomia & non- macrosomia babies. 
Weight gain was significantly different. 
 
 























3.9 Fat and pregnancy outcomes  
Table 9a: Macrosomia  
 Non macrosomia 
        (n=15) 
     Mean (SD) 
     Macrosomia 
          (n=11) 
       Mean (SD) 
T test 
Trimester 1        
SFA                     g/d 32.1 ± 7.2 29.5 ± 10.5 0.448 
MUFA                 g/d        30.9 ± 7.3 25.5 ± 10.3 0.132 
PUFA                  g/d 10.3 ± 4.3 10.9 ± 3.9 0.156 
Omega 3 FA        g/d   3.1 ± 1.3   3.0 ± 1.5 0.903 
Omega 6 FA       g/d 10.6 ± 3.6   7.5 ± 3.0 0.027 
Trimester 2   (n= 11)  (n= 13)  
SFA                    g/d 35.2 ± 3.3 34.5 ± 13.3 0.863 
MUFA                g/d 30.6 ± 7.2 29.5 ± 10.8 0.777 
PUFA                 g/d 15.5 ± 7.4 14.3 ± 7.8 0.717 
Omega 3 FA      g/d   4.0 ± 2.2   2.7 ± 1.7 0.118 
Omega 6 FA      g/d 11.5 ± 5.2 11.5 ± 6.5 0.973 
Trimester 3 (n=10)  (n=9)  
SFA                    g/d 30.8 ± 9.6 34.7 ± 12.6 0.459 
MUFA               g /d 34.9 ± 15.7 31.0 ± 11.4 0.548 
PUFA                g/d 16.2 ± 9.9 12.9 ± 4.9 0.380 
Omega 3 FA      g/d  3.4 ± 1.8   3.0 ± 2.0 0.650 
Omega 6 FA      g/d 12.7 ± 7.9   9.6 ± 3.8 0.297 
Table 10a: Fat and pregnancy outcomes – Macrosomia. 
SFA- saturated fatty acids, MUFA - monounsaturated fatty acids, PUFA - polyunsaturated fatty acids, E%- 
energy percent, Omega 3 FA - Omega 3 fatty acids, Omega 6 FA - Omega 6 fatty acids 
 
Diet records of 1st trimester show that there was no significant difference in intake of SFA, 
MUFA, PUFA, or omega 3 fatty acids between the groups. There was a significant difference 
in the intake of omega 6 fatty acids in 1st trimester. No significant differences in dietary were 













Table 9b: Prematurity   
        Term 
      (n=19) 
  Mean (SD) 
Prematurity 
      (n=7) 
  Mean (SD) 
T test 
Trimester 1        
SFA                 g/d 29.9 ± 8.9 33.9 ± 7.9 0.318 
MUFA             g/d        29.2 ± 8.2 27.3 ± 11.2 0.645 
PUFA              g/d 12.4 ± 3.9 12.4 ± 3.9 0.828 
Omega 3          g/d   3.3 ± 1.4   2.4 ± 0.9 0.164 
Omega 6          g/d   9.4 ± 3.2   8.9 ± 4.9 0.735 
trimester 2   (n= 18)    (n=6)  
SFA                 g/d 37.8 ± 8.6 25.8 ± 8.2 0.007 
MUFA            g/d 32.2 ± 9.3 23.5 ± 4.7 0.410 
PUFA             g/d 15.8 ± 8.4 11.8 ± 1.6 0.265 
Omega 3         g/d   3.7 ± 2.2   2.2 ± 0.4 0.119 
Omega 6         g/d 12.3 ± 6.5   9.0 ± 1.4 0.231 
Table 11b: Fat and pregnancy outcomes – Prematurity. 
SFA- saturated fatty acids, MUFA - monounsaturated fatty acids, PUFA - polyunsaturated fatty acids, E%- 
energy percent, Omega 3 FA - Omega 3 fatty acids, Omega 6 FA Omega 6- fatty acids 
 
No significant differences were observed in dietary intake in the 1st trimester according to the 
prematurity was observed. 













In this study involving 49 pregnant women with PGDM, we observed significant associations 
of metabolic control with birth outcomes (z score of birth weight and gestational age at birth). 
Among 26 women who submitted dietary records in the 1st trimester, we observed few 
significant associations of dietary intake with birth weight, but no significant differences 
according to macrosomia. Macrosomia was associated with gestational weight gain, but not 
with dietary intake. 
Women with preterm delivery had low intakes of energy, fat, and protein in the 2nd trimester. 
4.1 Strengths and limitations 
One strength of the study is that the design is a longitudinal observational one. This study is 
part of a larger project which was done by a multidisciplinary team of a tertiary unit. The 
study had a low dropout rate and good compliance of study visits with voluntary participation. 
The participants in this study were well educated, 93% of participants have above 13 years of 
education including 44% of participants have 17 years of education.  Dietary intake data were 
obtained from dietary records, which is regarded as the gold standard method. Measurement 
of dietary intake was repeated during each trimester, and there were very few studies that 
performed this. Participants were unaware of the outcome of pregnancy when they took food 
records, so pregnancy outcome could not affect the reporting.   
The obvious limitation of this study is the size of the study group. Out of 49 participants, 53% 
in 1st trimester 49% in 2nd trimester and 39% in 3rd trimester submitted food records. Due to 
circumstances beyond our control, we could not get 100% data collection. The pre-pregnancy 
BMI was calculated from the self-reported pre-pregnancy weight.    
The study group consists of type 1 and type 2 DM participants. Type 1 and type 2 DM differ 
in many ways. Pre-gravid BMI, gestational weight gain and metabolic control are 
significantly associated with pregnancy outcomes. Pre-pregnancy BMI is usually higher in 
type 2 DM than type 1 DM. Even though both types have similar treatment, poorer neonatal 






4.2 Discussions of results 
 Pregnant women with DM have been related to numerous maternal and fetal complications. 
Therefore, the cesarean section is high in these mothers. Cesarean birth in Norway in 2018 is 
15.9% but in this study group, 45% of birth were cesarean birth, which is much higher. All 
cesarean birth in Hordaland region is only 11.6% (6). Macrosomia affects 3-15% of all 
pregnancies in the population (68) but in this study, it affects around 39% of babies. 
Macrosomia is associated with difficult delivery results in trauma to the mother and the fetus 
and increased risks of cesarean section (88).  
Studies have shown that Hb1Ac % in at conception, 1st trimester (82), 2nd trimester (83), and 
3rd trimester (84) of pregnancy were associated with macrosomia. According to the Pederson 
hypothesis, maternal high blood glucose results in transplacental diffusion of a higher amount 
of glucose to the fetus, resulting in increased fetal insulin secretion. This leads to fetal 
macrosomia (92).  However, despite good glycemic control, the incidence of fetal 
macrosomia in Type I diabetic women was high (84,85,). Anyway, there is not enough 
investigation done about birthweight and its association with maternal diet during pregnancy.  
The mean birth weight of this study group was higher (3591± 892 g) than the average birth 
weight of Norway in 2018 (3490±585g). Pre-pregnancy BMI was 26.8 ± 5.4 kg/m2 in this 
study which is higher than the average pre-pregnancy BMI in Norway in 2018 which was 
24.5 ± 4.8 kg/m2 (6, 86). Pre-gravid BMI and maternal weight gain are positively associated 
with birth weight in a study from Australia involving with 1617 mothers with diabetes (87). In 
our study, pre-pregnancy BMI was not different between women who had a child with or 
without macrosomia. This may be due to a low number of participants or good pre-pregnancy 
awareness. Even though pre-gravid BMI between women with macrosomia baby and women 
with non-macrosomia baby is no significant difference, gestational weight gain was 
significantly higher in women with macrosomia baby (p: 0.012). A study showing that Type 1 
diabetes women with higher gestational weight gain was associated with macrosomia 
independent of pre-pregnancy BMI and glycemic control in late pregnancy (97). 
There are guidelines for appropriate maternal weight gain with pre-pregnancy BMI. What 
extent is it compatible to women with PGDM? 
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Pregnant women with diabetes are recommended to restrict their intake of carbohydrates 
which may result in improved maternal glycemia. However, carbohydrates have a very varied 
effect on blood glucose levels and metabolic control, which is usually expressed by the 
glycemic index. Diabetic women are advised to consume carbohydrate containing food with 
low glycemic index (95). Unfortunately, we do not have any data on the GI of carbohydrates 
in our study.  
Anyway, it seems to be better to include high quality carbohydrates with lower glycemic 
index and food containing lower fat. Replacement of lower glycemic index carbohydrates 
reduces the need for insulin and improves post-meal glycemia and maternal glucose and 
lowers infant birthweight in diabetic mother (94). The type of carbohydrate intake would be a 
factor in glycemic control rather than the amount of carbohydrate consumed. The 
carbohydrate should be distributed to maintain optimal glycemic control and to avoid 
hypoglycemia and ketonemia (95). 
Intake of dietary fiber in the 1st and 2nd trimester was lower in mothers who delivered 
macrosomia babies in this study. Intake of 44 to 50 g/d of fiber in diet reported to improve 
glycemia, but usual fiber intake (up to 24 g/d) in the diet has not shown positive effects on 
glycemia (95).   
Intake of omega 6 fatty acids during the 1st trimester was significantly low in women who had 
macrosomia babies (P: 0.027). According to a study in Korea, despite sufficient levels of 
omega-3 fatty acids, women who had high levels of omega-6 fatty acids delivered infants at 
low birth weight. Birth weight was inversely correlated with maternal omega-6 FA intake 
(93).   
Premature birth in Norway is 5.5% but, in our study, it is 31%. We had no information for the 
reasons for premature birth in the cohort, it has been reported that polyhydramnios (excess 
amniotic fluid) is an independent risk factor for spontaneous premature birth in pre- 
gestational diabetes women (89). The mean z-score of birth weight was higher in premature 
babies than in babies who delivered at term. Women who delivered preterm babies had a 
higher mean HbA1c level than women who delivered term babies. Mean z-score birth weight 
could be higher due to worse metabolic control indicated by higher HbA1c level in preterm 
delivered mothers. Strict glycemic control during pregnancy reduces the risk of spontaneous 
preterm delivery (101). 
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Nutrition during pregnancy is the only way to provide the essential nutrients for fetal growth. 
An imbalance diet during pregnancy may be a vital factor linked with preterm birth (106). In 
our study, energy intake in 2nd trimester was significantly lower in preterm delivery mothers 
compared to normal delivery mothers (p- value: 0.003). Dietary intake in 2nd trimester was 
much lower than recommended by IOM and NNR (78). Low dietary intake in 2nd trimester 
was associated with preterm delivery, indicating that dietary intake may have been inadequate 
in these women. There is a case-control study in India suggests that low protein and energy 
intake during pregnancy is possibly associated with preterm delivery (102). 
In addition to the total energy intake and carbohydrates, also the intake of saturated fatty acids 
in 2nd trimester was significantly lower in women who delivered preterm babies than women 
who delivered term babies (P: 0.007). This could be due to the restriction of fat intake to 
reduce maternal weight. 
A case control study from China showed that women in preterm infants had lower intake of 
fat than women in full-term infants (107). Dietary intake of fat plays a role in preventing 
preterm births. A study of Poland found this result already (109). 
Dietary fiber intake in 1st trimester in mothers with preterm delivery was significantly lower 
than mothers with at term delivery (p- value: 0.041). Increased soluble fiber improves blood 
glucose control and promotes regularity in diabetes mellitus and enhances insulin sensitivity 
(44). There are consistent but limited evidence indicates that certain food patterns during 
pregnancy are related with a lower risk of preterm birth. These protective food patterns are 
higher in fruits, vegetables, salad, whole grains. nuts, legumes, seeds, and fish and lower in 
red meat and processed meat products and fried foods. (108) 
In general, the maternal diet must give an adequate supply of energy to support the mother’s 
requirements as well as those of the growing fetus. While preventing maternal obesity is 
important to reduce the risk of macrosomia infants, and maternal and childbirth complications 
benefits of energy restriction must be judged against possible harms including intrauterine 
growth retardation.  
Besides diet, other factors affect gestational weight gain and birth weight. Pregnant women 
who do regular exercise are expected to have an appropriate gestational weight gain and 
healthy birth weight infant. Regular physical activity reduces circulating blood glucose level. 
Proper energy intake, hydration is important before, during and after activity (103). There are 
many factors affecting weight gain during pregnancy including pre-pregnancy BMI, age, 
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parity, dietary practices, physical activity, physiological, social, and psychological factors 
(61). 
The average intake of carbohydrates and added sugars were within recommended levels in 
this study. This may reflect the participant's awareness of carbohydrates and effects on blood 
glucose. Anyway, the mean intake of dietary fiber is of the lower limit of the recommended 
range (25-35 g /day) in 1st trimester, lower than the recommended requirement in 2nd 
trimester according to the guideline. According to this study, adequate intake of dietary fiber 
particularly during the 1st and 2nd trimester was associated with a lower z score of birth weight 
and increased gestational age at birth. Inadequate intake of dietary fiber is closely related to 
premature birth and large for gestational age babies. If enough fiber was eaten during the 1st 
and 2nd trimester, it would have reduced the chance of macrosomia baby. Dietary fiber slows 
the absorption of sugar and helps improve blood sugar levels, decreasing the chance of 
constipation, lower total blood cholesterol levels by lowering low-density lipoprotein, 
reducing weight by law calorie value (1-2kcal/ g),  fibrous foods can also contain antioxidants 
(e.g.- oats, beans) (90). Adequate fiber intake in obese significantly promotes weight loss 
(44).    
Intake of SFA E% is high, even though the intake of energy proportion of total fat was within 
the recommended range, the proportion of SFA exceeded the dietary recommendations in 
each trimester. Intake of PUFA was the lower half of the recommended range. A high intake 
of SFA is associated with high LDL - cholesterol concentrations. (99,78) There is strong 
evidence that replacing dietary SFA with unsaturated fatty acids, both MUFA and PUFA and 
carbohydrates from fiber-rich whole grains, protein from plant sources benefit cardiovascular 
health. (100) 
 
Generally, mothers’ weight, Hb1Ac is positively correlated with Z-score birth weight & 
negatively correlated with gestational age at birth. Hb1Ac is an indicator of average blood 
glucose level, but it may not reflect daily blood glucose variation that may reflect on 
pregnancy outcomes, such as hypo and hyperglycemia. Even though we have good health 
status, still there is a challenge for nutritionists and health staff to change the diet and lifestyle 
of women with PGDM. Pre-pregnancy care including planned pregnancy, controlling other 
diseases, glycemic control, and appropriate weight should be achieved to get a healthy 
pregnancy outcome. Pre-gravid and early prenatal dietary counselling encouraging healthy 
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dietary intake could improve pregnancy outcomes (104). Well-designed interventions and 
studies on how to implement the existing recommendations are most likely needed.  
5. Conclusion 
This study, one of the first to investigate dietary intake longitudinally during pregnancy. Even 
though the number of women were small, it is striking that the women did on average not 
increase their dietary intake from the 1st to 2nd trimester, and that the increase in 3rd trimester 
was much lower than recommended. Low dietary intake in 2nd trimester was associated with 
prematurity, which is an important pregnancy outcome. We propose that the dietary intake of 
women with pregestational diabetes should be better investigated and the focus should be on 
sufficient energy intake with maintaining metabolic control at the same time. More studies are 
required that investigate dietary intake in pregnant women with pre-gestational diabetes. 
6. Recommendations  
More research is required to understand the association of pre-conception dietary intake with 
birth weight, gestational age at birth in pre- gestational diabetic women. 
A study of dietary intake, maternal lifestyle (especially physical activity) and glycemic 
control with pregnancy outcome in PGDM mothers will give interesting results. 
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